enrox flavour 15 mg tablets for dogs and cats
krka, d.d., novo mesto - enrofloxacin - tablet - 15 mg/tablet - enrofloxacin - cats, dogs - antibacterial
enrox flavour 150 mg tablets for dogs
krka, d.d., novo mesto - enrofloxacin - tablet - 150 mg/tablet - enrofloxacin - dogs - antibacterial
enrox flavour 50 mg tablets for dogs
krka, d.d., novo mesto - enrofloxacin - tablet - 50 mg/tablet - enrofloxacin - dogs - antibacterial
vidalta 10 mg prolonged-release tablets for cats
intervet ireland limited - carbimazole - tablet - 10 mg/tablet - carbimazole - cats - hormone
vidalta 15 mg prolonged-release tablets for cats
intervet ireland limited - carbimazole - tablet - 15 mg/tablet - carbimazole - cats - hormone
apo-omeprazole omeprazole 20 mg enteric-coated tablet blister pack
arrotex pharmaceuticals pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide black; microcrystalline cellulose; povidone; iron oxide red; crospovidone; purified talc; lactose monohydrate; hypromellose phthalate; magnesium stearate; triacetin; ascorbyl palmitate - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.
omeprazole generichealth omeprazole 20 mg enteric-coated tablet bottle
southern cross pharma pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; ascorbyl palmitate; povidone; purified talc; iron oxide red; iron oxide black; lactose monohydrate; magnesium stearate; hypromellose phthalate; crospovidone; triacetin - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.
omeprazole generichealth omeprazole 20 mg enteric-coated tablet blister pack
southern cross pharma pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide black; microcrystalline cellulose; povidone; iron oxide red; crospovidone; purified talc; lactose monohydrate; hypromellose phthalate; magnesium stearate; triacetin; ascorbyl palmitate - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.
citalopram an citalopram hydrobromide 40 mg tablet bottle
amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 49.96 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: copovidone; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; purified water; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression
citalopram an citalopram hydrobromide 20 mg tablet bottle
amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 24.98 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; copovidone; microcrystalline cellulose; purified water; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for treatment of major depression